The two earthquakes that recently struck the northern coast of Venezuela will deepen a health crisis that has troubled the country for twenty years. They have exposed how weak its health infrastructure is, how scarce medicines are, how little epidemiological surveillance remains, and how long investment has been lacking. The humanitarian health crisis in Venezuela did not arise from armed conflict, as it has elsewhere. Its roots lie in decades of authoritarian rule and institutional decay, which have eroded public health capacity, research infrastructure, vaccination coverage and the control of infectious diseases in general. Because these weaknesses have accumulated, the earthquakes may well turn into an even graver humanitarian emergency. Recovery that lasts will not be secured by short-term international aid alone. It will require the rebuilding of accountable institutions able to govern transparently and to apply equitable health policies, so that the health system can regain its resilience.
Background Metabolic dysfunction–associated steatotic liver disease (MASLD) is highly prevalent and frequently undiagnosed, despite liver fibrosis being the strongest predictor of liver-related morbidity and mortality. We aimed to quantify Fibrosis-4 (FIB-4) index-based fibrosis risk and to evaluate guideline-recommended follow-up—FIB-4 documentation, confirmatory testing, and specialist referral—in a large US cohort. Methods We conducted a retrospective study of electronic health record data from the US All of Us Research Program. Among adults aged 35 years or older with sufficient laboratory data, FIB-4 scores were calculated from routinely captured biomarkers, classified as low (<1.3), indeterminate (1.3–2.67; 2.0–2.67 if aged ≥65 years), or high risk (>2.67), and described across sociodemographic and metabolic subgroups; associations with incident major adverse liver outcomes (MALO) were assessed with Cox proportional-hazards regression. We examined FIB-4 documentation, confirmatory testing, and specialty referrals within 365 days of the index FIB-4 date. Findings Among 136,004 participants (mean age 60.8 years [SD 13.5]; 79,365 [58.4%] female; 81,420 [59.9%] White, 21,779 [16.0%] Hispanic or Latino, 20,076 [14.8%] Black), 26,971 (19.8%, 95% CI 19.6–20.0) had indeterminate and 11,217 (8.2%, 8.1–8.4) high FIB-4–based fibrosis risk. Elevated risk was more frequent with cardiovascular disease (41.7% vs 25.6%), hypertension (30.7% vs 23.4%), and type 2 diabetes (29.7% vs 27.4%), rising from 25.6% with no metabolic comorbidities to 36.6% with four. FIB-4 documentation was rare, and fewer than 1% of high-risk participants underwent confirmatory testing or referral; referral was low across risk categories (0.19% high, 0.19% indeterminate, 0.25% low risk). MALO occurred in 1308 (11.7%) high-risk vs 830 (0.8%) low-risk participants (adjusted hazard ratio 19.68, 95% CI 17.88–21.67). Interpretation Routinely collected laboratory data identify substantial liver fibrosis risk in this volunteer US cohort, yet guideline-recommended follow-up is uncommon. Implementation strategies such as automated risk calculation and reflex-based testing pathways could reduce missed opportunities for earlier diagnosis and intervention. Funding No specific funding was received for this study.
Objectives This is a scale-up report on the SMART (Self-management for people with epilepsy and a history of negative health events) epilepsy self-management (ESM) program. Methods Engagement in SMART was assessed via session attendance (maximum of 8). Outcomes included the 10-item Quality of Life in Epilepsy (QOLIE-10), Generalized Anxiety Disorder scale (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) and past 30-day seizure frequency. Results 153 PWE were referred to ESM, mean age 37.6 (SD 12.8). Average attendance for PWE who attended ≥ 1 session (N = 115) was 5.8 (SD 2.6). There were no significant pre/post changes for QOLIE-10, NDDI-E, GAD-7, PHQ-9 or past 30-day seizure counts. Exploratory analysis of clinically relevant subgroups found PWE with PHQ-9 ≥ 10 at baseline (N = 27), had significant improvement pre/post SMART with means of 15.0 (SD 4.5) and 11.7 (SD 5.1), respectively (p = 0.001), those with GAD-7 ≥ 10 at baseline (N = 31) had significant improvement pre/post SMART with means of 14.4 (SD 3.2) and 11.2 (SD 3.8), respectively (p = 0.001) and those in the lowest quartile of QOLIE-10 scores (N = 16) had significant improvement pre/post SMART with means of 3.8 (SD 0.5) and 3.4 (SD 0.8), respectively. Discussion This analysis from a real-world, non-research study sample suggests scaling up ESM in an epilepsy-care clinical setting appears feasible, acceptable to PWE, and can improve outcomes for PWE with depression, anxiety and suboptimal quality of life. Future work needs to address barriers to generalizability.
The therapeutic potential of oligonucleotides (oligos) is limited by insufficient delivery to extrahepatic tissues. In vitro assays often fail to accurately predict in vivo behavior, while testing each oligo candidate in animals remains inherently low throughput. Here, we conceive a barcoded oligonucleotide system (BOLT), a platform that enables high-throughput in vivo evaluations of small-molecule ligands and identifies tissue-specific oligo delivery. BOLT integrates rational design of oligo barcodes, modular conjugation chemistry, and next-generation sequencing (NGS)-based quantification, allowing simultaneous evaluation of many chemically diverse ligand-oligo conjugates within a single animal. Notably, this platform is applicable in both mice and nonhuman primates (NHPs). Using BOLT, we discovered ligands with tropism for tissues such as the brain, lung, and muscle. Collectively, these results indicate that the BOLT platform can accelerate the discovery of tissue-targeting ligands for broad oligo therapeutics.